


### AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An oxygen infusion for increasing an oxygen concentration in tumor tissues in living bodies, said oxygen infusion comprising a dispersion of an albumin clathrate compound including porphyrin metal complex, dispersed in a physiologically permissible aqueous media, wherein said porphyrin metal complex is a porphyrin metal complex represented by the general formula (I):



~~where R<sub>1</sub> is a chain or alicyclic hydrocarbon group that may have one or more substituents, R<sub>2</sub> is a basic axial ligand expressed by the formula (A):~~


wherein R<sub>1</sub> is:

- a C<sub>1</sub>-C<sub>19</sub> chain hydrocarbon group having dimethyl groups at the first position; or
- a C<sub>3</sub>-C<sub>19</sub> alicyclic hydrocarbon group having a substituent at the first position,

wherein each substituent is a methyl, C<sub>1</sub>-C<sub>18</sub> alkylamide, C<sub>1</sub>-C<sub>18</sub> alkanoyloxy, or C<sub>1</sub>-C<sub>18</sub> alkoxy;

R<sub>2</sub> is a basic axial ligand expressed by the formula (A):


Formula (A)



[[wherein]] wherein  $R_3$  is alkylene, a  $C_1-C_{10}$  alkylene; and

~~R<sub>4</sub> is a group that does not inhibit coordination of said basic axial ligand to a central transition metal ion M, and M is a transition metal ion of the 4th or 5th period of the periodic table of elements. hydrogen, methyl, ethyl, propyl or a basic axial ligand represented by the formula (B):~~

Formula (B)




---

wherein  $R_5$  is a  $C_1-C_{10}$  alkylene;

$R_6$  is a  $C_1-C_{18}$  alkyl; and

M is a transition metal ion of the 4th or 5th period of the periodic table of elements.

2. (Cancelled)

3. (Previously presented) The oxygen infusion according to claim 1, wherein said porphyrin metal complex is a porphyrin metal complex of the general formula (I), in which  $R_1$  is  $C_3-C_{19}$  alicyclic hydrocarbon having a substituent at the first position,  $R_2$  is a basic axial ligand

expressed by the formula (A) where R<sub>3</sub> is C<sub>1</sub>-C<sub>10</sub> alkylene, R<sub>4</sub> is hydrogen, methyl, ethyl or propyl, and M is Fe or Co.

4. (Cancelled)

5. (Previously presented) The oxygen infusion according to claim 1, wherein said porphyrin metal complex is a porphyrin metal complex of the general formula (I), in which R<sub>1</sub> is a C<sub>1</sub>-C<sub>19</sub> chain hydrocarbon group having dimethyl groups at the first position, R<sub>2</sub> is a basic axial ligand expressed by the formula (A) where R<sub>3</sub> is C<sub>1</sub>-C<sub>10</sub> alkylene, R<sub>4</sub> is hydrogen, methyl, ethyl or propyl and M is Fe or Co.

6. (Cancelled)


7. (Previously presented) The oxygen infusion according to claim 1, wherein said porphyrin metal complex is 2-8-(2-methyl-1-imidazolyl)octanoyloxymethyl-5, 10, 15, 20-tetrakis-( $\alpha,\alpha,\alpha,\alpha$ -o-pivaloylamidophenyl)porphyrin iron (II) complex.

8. (Previously presented) The oxygen infusion according to claim 1, wherein said porphyrin metal complex is 2-8-(1-imidazolyl)octanoyloxymethyl-5, 10, 15, 20-tetrakis-( $\alpha,\alpha,\alpha,\alpha$ -o-(1-methyl cyclohexanoyl) aminophenyl) porphyrin iron (II) complex.

9. (Currently amended) The oxygen infusion according to claim 1, wherein said albumin clathrate compound further includes a porphyrin metal complex represented by the general

formula (II):

General formula (II)




where R<sub>7</sub> is hydrogen or a chain hydrocarbon group that may have optionally having one or more substituents,

R<sub>8</sub> is alkyloxy, alkylamino, or an amino acid or amino acid derivative residue,


R<sub>9</sub> is a basic axial ligand represented by the formula (C):

Formula (C)



where R<sub>10</sub> is alkylene, R<sub>11</sub> is a group that does not inhibit coordination of said basic axial ligand to a central transition metal ion M a hydrogen, methyl, ethyl, propyl or a basic axial ligand represented by the formula (D):

Formula (D)



---

wherein R<sub>12</sub> is an alkyl, and an


M is a transition metal ion of the 4th or 5th period of the periodic table of elements.

10. (Previously presented) The oxygen infusion according to claim 9, wherein said albumin clathrate compound includes a porphyrin metal complex of the general formula (II), in which R<sub>7</sub> is hydrogen, vinyl, ethyl or methoxy, R<sub>8</sub> is C<sub>1</sub>-C<sub>18</sub> alkyloxy, C<sub>1</sub>-C<sub>18</sub> alkylamino, an amino acid or a derivative residue of the amino acid, R<sub>10</sub> is C<sub>1</sub>-C<sub>10</sub> alkylene, R<sub>11</sub> is hydrogen, methyl, ethyl or propyl, and M is Fe or Co.

11. (Previously presented) The oxygen infusion according to claim 9, wherein said albumin clathrate compound includes a porphyrin metal complex of the general formula (II), in which said one or more substituents are selected from the group consisting of methyl, C<sub>1</sub>-C<sub>18</sub> alkylamide, C<sub>1</sub>-C<sub>18</sub> alkanoyloxy and C<sub>1</sub>-C<sub>18</sub> alkoxy.


12. (Previously presented) The oxygen infusion according to claim 9, wherein said porphyrin metal complex of the general formula (II) is 8,13-bisvinyl-2-methoxycarbonylethyl-18-(3-(1-imidazolyl) propylamino) carbonylethyl-3,7,12,17-tetramethyl porphyrin iron (II) complex.

13. (Previously presented) The oxygen infusion according to claim 1, where said albumin clathrate compound further includes a porphyrin metal complex represented by the general formula (II):



wherein R<sub>7</sub> is hydrogen or a chain hydrocarbon group that may have one or more substituents, R<sub>8</sub> is alkyloxy, alkylamino, or an amino acid or amino acid derivative residue, R<sub>9</sub> is a basic axial ligand expressed by the formula (D):

Formula (D)



where R<sub>12</sub> is alkyl, and M is a transition metal ion of the 4<sup>th</sup> or 5<sup>th</sup> period of the periodic table of elements.

14. (Previously presented) The oxygen infusion according to claim 13, wherein R<sub>7</sub> is hydrogen, vinyl, ethyl or methoxy, R<sub>8</sub> is C<sub>1</sub>-C<sub>18</sub> alkyloxy, C<sub>1</sub>-C<sub>18</sub> alkylamino, amino acid or a derivative residue thereof, R<sub>12</sub> is C<sub>1</sub>-C<sub>18</sub> alkyl, and M is Fe or Co.

15. (Previously presented) The oxygen infusion according to claim 13, wherein said albumin clathrate compound includes a porphyrin metal complex of the general formula (II), in which said one or more substituents are the ones selected from the group consisting of methyl, C<sub>1</sub>-C<sub>18</sub> alkylamide, C<sub>1</sub>-C<sub>18</sub> alkanoyloxy and C<sub>1</sub>-C<sub>18</sub> alkoxy.